Axsome Therapeutics Inc (OQ:AXSM)

Sector:  Healthcare Industry:  Pharmaceuticals
 
See Regulatory Filings on SEC
Company Contact
Address: One World Trade Center, 22Nd Floor
NEW YORK NY 10007
Tel: N/A
Website: https://www.axsome.com
IR: See website
<
Key People
Herriot Tabuteau
Chairman of the Board, President, Chief Executive Officer, Founder
Nick Pizzie
Chief Financial Officer
Mark L. Jacobson
Chief Operating Officer
Lori Englebert
Executive Vice President - Commercial and Business Development
Hunter Murdock
General Counsel
 
Business Overview
Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in developing and delivering therapies for central nervous system (CNS), conditions that have limited treatment options. The Company's two commercial products and development programs are Auvelity and Sunosi. Auvelity (dextromethorphan-bupropion) is an oral, N-methyl-D-aspartate (NMDA) receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder (MDD). Sunosi (solriamfetol) is an oral medication indicated for the treatment of excessive daytime sleepiness (EDS), in patients with narcolepsy or obstructive sleep apnea. AXS-05 is an oral, investigational NMDA receptor antagonist with multimodal activity under development for the treatment of Alzheimer's disease agitation (AD agitation) and smoking cessation. AXS-07 is an oral, rapidly absorbed, multi-mechanistic, investigational medicine under development for the acute treatment of migraine.
Financial Overview
For the three months ended 31 March 2024, Axsome Therapeutics Inc revenues decreased 21% to $75M. Net loss increased from $11.2M to $68.4M. Revenues reflect License revenue decrease from $65.7M to $0K. Higher net loss reflects General and administrative - other increase of 40% to $58.8M (expense), Research and development - Other increase from $14.3M to $29.7M (expense), Stock-based Compensation in SGA increase of 48% to $15.6M (expense).
Employees: 545 as of Feb 13, 2024
Reporting Currency: U.S. Dollars
Enterprise value: $3,503M as of Mar 31, 2024
Annual revenue (TTM): $251.02M as of Mar 31, 2024
EBITDA (TTM): -$285.72M as of Mar 31, 2024
Net annual income (TTM): -$296.38M as of Mar 31, 2024
Free cash flow (TTM): -$193.34M as of Mar 31, 2024
Net Debt Last Fiscal Year: N/A
Shares outstanding: 47,495,827 as of Apr 29, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.